- Home
- AMWD vs ANAB Comparison
AMWD vs ANAB Comparison
Compare AMWD & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMWD
- ANAB
- Stock Information
- Founded
- AMWD 1980
- ANAB 2005
- Country
- AMWD United States
- ANAB United States
- Employees
- AMWD N/A
- ANAB N/A
- Industry
- AMWD Forest Products
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- AMWD Basic Materials
- ANAB Health Care
- Exchange
- AMWD Nasdaq
- ANAB Nasdaq
- Market Cap
- AMWD 772.0M
- ANAB 621.1M
- IPO Year
- AMWD N/A
- ANAB 2017
- Fundamental
- Price
- AMWD $52.44
- ANAB $24.69
- Analyst Decision
- AMWD Buy
- ANAB Buy
- Analyst Count
- AMWD 4
- ANAB 10
- Target Price
- AMWD $83.33
- ANAB $49.00
- AVG Volume (30 Days)
- AMWD 111.5K
- ANAB 516.1K
- Earning Date
- AMWD 08-26-2025
- ANAB 08-08-2025
- Dividend Yield
- AMWD N/A
- ANAB N/A
- EPS Growth
- AMWD N/A
- ANAB N/A
- EPS
- AMWD 6.50
- ANAB N/A
- Revenue
- AMWD $1,709,585,000.00
- ANAB $111,872,000.00
- Revenue This Year
- AMWD N/A
- ANAB N/A
- Revenue Next Year
- AMWD $4.03
- ANAB $24.39
- P/E Ratio
- AMWD $8.09
- ANAB N/A
- Revenue Growth
- AMWD N/A
- ANAB 387.20
- 52 Week Low
- AMWD $50.00
- ANAB $12.21
- 52 Week High
- AMWD $106.57
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- AMWD 41.76
- ANAB 45.70
- Support Level
- AMWD $51.66
- ANAB $23.61
- Resistance Level
- AMWD $56.57
- ANAB $28.50
- Average True Range (ATR)
- AMWD 2.27
- ANAB 1.24
- MACD
- AMWD -0.19
- ANAB -0.35
- Stochastic Oscillator
- AMWD 21.44
- ANAB 22.17
About AMWD American Woodmark Corporation
American Woodmark Corp manufactures and distributes cabinets and vanities for the remodeling and new home construction markets. It offers several products that fall into product lines including kitchen cabinetry, bath cabinetry, office cabinetry, home organization, and hardware. The products are sold under the brand names American Woodmark, Timberlake, Shenandoah Cabinetry, and Waypoint Living Spaces among others.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).